Route of Administration |
Dosage Form / Strength/Composition |
Non-medicinal Ingredients |
---|---|---|
Oral (co-packaged for use) |
Nirmatrelvir Tablet (pink): 150mg
|
Tablet core: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate Film coat: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol and titanium dioxide |
Ritonavir Tablet (white): 100mg |
Tablet core: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate. Film coat: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 80, talc and titanium dioxide. |
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. It is supplied in two different Dose Packs.
Nirmatrelvir tablets and ritonavir tablets are supplied in separate cavities within the same child resistant blister card.
Dose Packs |
Content |
Description |
---|---|---|
300 mg nirmatrelvir; 100 mg ritonavir |
Each Carton Contains: |
Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
Each Blister Carda Contains: |
Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
|
150 mg nirmatrelvir; 100 mg ritonavir |
Each Carton Contains: |
Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
Each Blister Carda Contains: |
Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
|
|